Positives

• Patients with mitochondrial fatigue describe elamipretide as one of the more biologically plausible peptide options because it specifically targets cardiolipin in the inner mitochondrial membrane, the structure damaged in Long COVID.
  
  
• A patient reported subjective improvement in exertion tolerance after several weeks of subcutaneous dosing, consistent with the small mitochondrial myopathy literature.
  
  

Negatives

• Patients commonly report disappointment when long-term studies in primary mitochondrial myopathy failed to show meaningful gains in walk distance or fatigue at 24 weeks.
  
  
• One patient reported only mild injection-site reactions but no clear functional change, echoing the gap between mechanism and lived effect.
  
  

Hurdles & Side Effects

• Elamipretide remains an investigational drug with no FDA approval for fatigue or Long COVID, so access is essentially through compounding pharmacies or grey-market sources.
  
  
• Cost is prohibitive for many; patients describe sourcing-quality anxiety because purity of compounded or research-grade SS-31 cannot be independently verified.